CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER (CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER).
CLINIMIX E 5/15 is a parenteral nutrition solution that provides essential amino acids, electrolytes, and dextrose for intravenous use. Amino acids serve as building blocks for protein synthesis, dextrose provides calories for energy metabolism, and electrolytes maintain fluid and electrolyte balance. Calcium is essential for bone mineralization, neuromuscular function, and enzyme activation.
| Metabolism | Amino acids are metabolized in the liver via transamination, deamination, and the urea cycle. Dextrose is metabolized via glycolysis and the citric acid cycle. Electrolytes (including calcium) are not metabolized but are distributed and excreted renally. |
| Excretion | Renal excretion of amino acids and electrolytes; dextrose is metabolized to CO2 and water, with minimal renal excretion. Biliary/fecal elimination is negligible (<2%). |
| Half-life | Components have variable half-lives: amino acids ~0.5-1 h; dextrose ~2-4 h; electrolytes depend on renal function. Terminal half-life not applicable as a mixture. |
| Protein binding | Amino acids: Negligible protein binding (<5%). Dextrose: Not bound. Electrolytes: Variable (calcium ~40% bound to albumin; others minimal). |
| Volume of Distribution | Total parenteral nutrition components distribute throughout extracellular fluid; Vd ~0.2-0.3 L/kg for electrolytes and amino acids, reflecting ECF volume. |
| Bioavailability | Intravenous: 100% bioavailability. Not administered by other routes. |
| Onset of Action | Intravenous: Metabolic effects (e.g., rise in blood glucose, insulin secretion) begin within minutes to 15 minutes after infusion initiation. |
| Duration of Action | Duration depends on infusion rate; continuous infusion maintains therapeutic levels. After cessation, effects wane over 1-2 hours for glucose and amino acids. |
| Molecular Weight | Not applicable (mixture of compounds; dextrose 180.16 Da, amino acids 75-204 Da). |
Intravenous infusion. Typical adult dose: 1.5–2.0 L/day of CLINIMIX E 5/15 (providing 75–100 g amino acids and 225–300 g dextrose per day) administered via central line; rate determined by glucose tolerance and fluid status.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <25 mL/min) unless on renal replacement therapy; for GFR 25–50 mL/min, reduce dose by 25–50% and monitor electrolytes; GFR >50 mL/min: no adjustment needed. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce nitrogen load by 30–50%; Class C: avoid or use with extreme caution (risk of hyperammonemia). |
| Pediatric use | Individualized based on weight and metabolic needs. Typical: 1–2 g amino acids/kg/day and 10–15 mg/kg/min dextrose; infusion rate titrated to glucose tolerance; for neonates, start at 0.5 g amino acids/kg/day and increase gradually. |
| Geriatric use | Use with caution due to higher risk of fluid overload and glucose intolerance; monitor renal function and serum electrolytes; start at lower end of dosing range (e.g., 1 L/day) and adjust based on tolerance. |
| 1st trimester | Clinimix E 5/15 is an amino acid/dextrose/electrolyte solution. No adequate and well-controlled studies in pregnant women. Animal reproduction studies not conducted. Use only if clearly needed. |
| 2nd trimester | Same as T1. Consider maternal nutritional status and potential risks of parenteral nutrition. |
| 3rd trimester | Same as T1. May affect fetal glucose metabolism; monitor maternal glucose closely. |
Clinical note
Comprehensive clinical and safety monograph for CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER (CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER).
| Placental transfer | Components (amino acids, dextrose, electrolytes) readily cross placenta. No specific data on transfer of complete solution. |
| Breastfeeding | Excretion into breast milk unknown. Caution advised. Limited data; use only if clearly needed. |
| Lactation Rating | L3 (Moderately Safe) - no human studies suggesting risk. |
| Teratogenic Risk | Parenteral nutrition components are generally considered essential for maternal and fetal health when oral/enteral nutrition is inadequate. No teratogenic risks have been identified at recommended doses; however, each component (amino acids, dextrose, electrolytes, vitamins) must be individually assessed. First trimester: No known structural anomalies; used as needed. Second and third trimesters: No specific fetal risks; monitor for maternal metabolic disturbances (hyperglycemia, electrolyte imbalances) which can affect fetal growth. |
| Fetal Monitoring | Monitor maternal blood glucose, serum electrolytes (potassium, sodium, calcium, phosphate, magnesium), acid-base balance, liver function, and nitrogen balance. Fetal monitoring includes ultrasound for growth and amniotic fluid volume, and nonstress test if diabetic control is a concern. |
| Fertility Effects | No known adverse effects on fertility. Correction of nutritional deficiencies may improve fertility in malnourished women. |
■ FDA Black Box Warning
NOT FOR USE IN INFANTS OR NEONATES who are at risk of aluminum toxicity. Premature infants are particularly at risk because of immature renal function. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration in patients with renal impairment.
| Serious Effects |
Hypersensitivity to any componentSevere electrolyte disorders (e.g., hyperkalemia, hypercalcemia)Inborn errors of amino acid metabolismSevere hyperglycemiaSulfite allergy (contains sulfites)
| Precautions | Risk of hyperglycemia requiring monitoring of blood glucose and insulin administration, Risk of electrolyte imbalances including hypercalcemia, hyperkalemia, and hyperphosphatemia, Risk of aluminum toxicity, especially in neonates and patients with renal impairment, Risk of infection from catheter-related bloodstream infections, Risk of fluid overload, particularly in patients with renal or cardiac insufficiency, Monitoring of liver function tests, serum electrolytes, blood glucose, and osmolality required |
| Food/Dietary | Enteral nutrition is not administered concurrently; TPN replaces oral intake. No specific food interactions, but oral intake should be discussed with the healthcare team if transitioning to enteral feeding. |
| Clinical Pearls | This is a total parenteral nutrition (TPN) formulation containing 15% dextrose, 5% amino acids, electrolytes, and calcium. Use strict aseptic technique for preparation and administration. Monitor serum glucose, electrolytes, renal and hepatic function regularly. Do not add other medications unless compatibility is verified. Inspect for precipitation, especially with calcium and phosphate. Adjust infusion rate gradually to avoid hyperglycemia and rebound hypoglycemia. |
| Patient Advice | This nutrition solution is given intravenously to provide complete nutrition when you cannot eat or drink. · Report any signs of infection at the IV site (redness, swelling, pain) or fever, chills, or shortness of breath. · Your blood sugar, electrolytes, and other lab values will be checked frequently. · Do not adjust the infusion rate yourself; it is controlled by the healthcare team. · Inform your healthcare provider if you have diabetes, kidney problems, or any allergies. |
Loading safety data…